Antisoma and Bryan Oncor announce deal for anti-cancer drug P2045
(Thomson Reuters ONE) - 11 August 2009 - London, UK, Cambridge, MA, and Somerville, MA:Antisoma plc (LSE: ASM; USOTC: ATSMY) and Bryan Oncor, Inc., aprivately held US biotechnology company, announce the assignment toBryan Oncor of all rights to P2045, a novel radiolabelledsomatostatin analogue that has completed a phase I trial in non-smallcell lung cancer. P2045 had been added to Antisoma's portfoliothrough the acquisition of Xanthus Pharmaceuticals, Inc. in June2008.P2045 co-inventor and former Antisoma scientist Dr. John Lister Jameswill continue with the clinical development of P2045 as ChiefTechnology Officer at Bryan Oncor.Glyn Edwards, Antisoma's CEO, said: "We are pleased that Bryan Oncorwill be taking P2045 forward, building on promising initial data froma phase I trial. We believe that successful development of thisproduct is best achieved by a company like Bryan Oncor that hasspecialist expertise in radiolabelled pharmaceuticals."Chris Adams, CEO of Bryan Oncor, Inc, said: "As an early stagecompany Bryan Oncor will focus its efforts on developing thispotentially important cancer therapeutic. There is a significantmedical need for drugs to treat lung cancer".Enquiries:Glyn EdwardsChief Exective OfficerAntisoma plc+44 (0)20 3249 2144Mark Court/Lisa Baderoon/Rebecca Skye DietrichBuchanan Communications+44 (0)20 7466 5000Brian KorbThe Trout Group+1 646 378 2923Chris AdamsChief Executive OfficerBryan Oncor, Inc.+1 617 957 9858info(at)bryanoncor.comBackground on P2045P2O45 is a radiopharmaceutical that comprises a high-affinitysomatostatin receptor binding peptide and the high-energybeta-emitting radionuclide rhenium-188 and has been shown to beeffective in cancer animal models and was well tolerated by patientsin a phase I clinical study.Background on AntisomaAntisoma is a London Stock Exchange-listed biopharmaceutical companythat develops novel products for the treatment of cancer. The Companyhas operations in the UK and the US. Please visitwww.antisoma.com for further information about Antisoma.Background on Bryan Oncor, Inc.Bryan Oncor is an early stage Massachusetts based biopharmaceuticalcompany focused on the development of oncology therapeutics.---END OF MESSAGE---This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 11.08.2009 - 13:01 Uhr
Sprache: Deutsch
News-ID 4583
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 376 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Antisoma and Bryan Oncor announce deal for anti-cancer drug P2045"
steht unter der journalistisch-redaktionellen Verantwortung von
Antisoma plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
